Table 2.
Analysis of the primary end point of clinically inactive disease at 12 months in each CTP group*
| Estimated % (95% CI) | Estimated difference (95% CI) | ||
|---|---|---|---|
| Compared to step‐up plan | Compared to biologic first plan | ||
| Unadjusted model† | |||
| Step‐up CTP | 32.3 (26.2, 39.0) (70/217) | – | 8.0 (−9.6, 25.7) |
| Early combination CTP | 37.2 (26.7, 48.9) (29/78) | 4.9 (−8.3, 18.2) | 12.9 (−7.4, 33.2) |
| Biologic first CTP | 24.2 (11.7, 42.6) (8/33) | – | – |
| Model with PS weighting and multiple imputation | |||
| Step‐up CTP | 37.8 (29.4, 46.2) | – | 4.2 (−14.8, 23.3) |
| Early combination CTP | 47.3 (32.6, 62.0) | 9.5 (−4.1, 23.2) | 13.7 (−8.2, 35.7) |
| Biologic first CTP | 33.6 (14.5, 52.6) | – | – |
*
P = 0.39 for the comparison of propensity score (PS)–weighted percentages between groups, by the Wald test, accounting for multiple imputation. There were no significant differences between any of the consensus treatment plans (CTPs).
†
Observed data were analyzed in the unadjusted model. Values are the estimated percentages of patients in whom clinically inactive disease was achieved (95% confidence interval [95% CI]) (no. of patients with clinically inactive disease/no. of patients assessed).